

TransMedics Group, Inc (TMDX US)

Bringing new life to organ transplant

COMPANY DESCRIPTION

Founded in 1998, TransMedics Group, Inc is a commercial-stage medical technology company headquartered in Andover, MA. TransMedics develops the FDA-approved, portable, multi-organ, warm perfusion platform – Organ Care System (OCS) to optimize, monitor, and preserve organ transplants. The company also develops a National OCS Program (NOP) to provide outsourced organ retrieval and organ procurement. 🚀

BUSINESS MODEL


TransMedics generates revenue from sales of its single-use OCS disposable set and OCS Consoles, as well as service revenue from outsourced organ retrievals and OCS organ management services. 🚀

IPO HISTORY


On 05/02/2019, TransMedics Group began trading on the NASDAQ Global Market led by Morgan Stanley. The organ preservation platform upsized 21% to offer 5,690,000 shares, at **\$16.00 per share**, mid-point of its expected price range (\$15-\$17). TransMedics was valued at ca. \$337 million at offer with the 15% over-allotment option fully exercised. The shares opened at \$20.25 and closed the first day higher at \$22.36 (▲39.75%). 🚀

TransMedics Group, Inc was included in the **IPOX® 100 U.S. Index** (ETF: FPX US, FPX LN) on 09/19/2022 and has gained ▲58.71% since addition to the index. 🚀

HISTORICAL PERFORMANCE



GROWTH OUTLOOK



INDUSTRY COMPARISON

COMPANY	STOCK SYMBOL	IPO/SPIN-OFF DATE	INITIAL RETURN	OFFER TO DATE (TR)	2023 YTD (PR)	BETA TO BENCHMARK	REVENUE (MILLIONS)	GROWTH YoY	EPS
TransMedics	TMDX US	05/02/2019	39.75%	258.09%	29.73%	1.35	\$93.46	208.83%	-\$1.23
XVIVO	XVIVO SS	Spin off from Vitrolife on 03/19/2012			24.86%	1.08	\$41.18	60.73%	\$0.061

TransMedics only identified two companies providing warm perfusion systems in direct competition, Xvivo Perfusion AB and OrganOx Limited (private). TransMedics Group also competes with cold storage and cold perfusion organ preservation transportation devices makers.